Shares in Flexion closed more than 10% higher in value Friday, although Monday morning trading had pared back a large portion of those gains.
Several other research analysts have also recently weighed in on the stock.
The approval could cast Flexion as a potential takeover target, according to RBC Capital Markets.
At the end of 06/30/2017 reporting period, 64 institutional holders increased their position in Flexion Therapeutics, Inc. Wells Fargo & Company set a $39.00 price objective on Flexion Therapeutics and gave the stock a "buy" rating in a research note on Friday.
Flexion Therapeutics, Inc. was covered by a number of analysts recently, 4 rated the stock as Buy, 4 rated Outperform, 0 rated Hold, 0 gave an Underperform and 0 rated sell.
If Tillerson called me a moron, 'we'll have to compare IQ tests'
Trump added in the Forbes interview that Tillerson was "wasting his time" when Tillerson appeared to be reopening talks with North Korea.
FLXN is now undervalued by -22.99% relative to the average 1-year price target of $36.67 taken from a group of Wall Street Analysts. FLXN stock price revealed optimistic move of 38.57% comparing average price of last 200 days. 1064156 shares were traded on Flexion Therapeutics Inc's last session.
A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future. The company has market cap of $901.02 million. It is now trading at $28.24 which is quite a bit higher than $24.68, the 50 day moving average and which is significantly above the 200 day moving average of $22.57. In this case, shares are 77.28% higher from $15.93, the worst price in 52 weeks suffered on November 08, 2016, and are keeping their losses at 6.09% for the past six months.
Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings data on Tuesday, August 8th. Comparatively, Flexion Therapeutics, Inc. posted earnings of $-0.82 per share in the same quarter a year ago.
10/09/2017 - Flexion Therapeutics Inc had its "buy" rating reiterated by analysts at Needham & Company.
TRADEMARK VIOLATION NOTICE: "Flexion Therapeutics, Inc".
PSG lining up a move for Red Devils ace David de Gea
PSG's director of football Antero Henrique is said to have already talked to De Gea's agent Jorge Mendes about the goalkeeper. As well as the Atlético Madrid goalkeeper, there's another potential target, and it's Manchester United's David De Gea .
The good news is there's still room for Flexion Therapeutics, Inc. The stock was acquired at an average cost of $24.15 per share, with a total value of $72,450.00. Following the acquisition, the insider now directly owns 5,000 shares of the company's stock, valued at $120,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock. Public Employees Retirement System of OH now owns 41,644 shares of the specialty pharmaceutical company's stock worth $842,000 after acquiring an additional 17,066 shares in the last quarter. Macquarie Group Ltd. now owns 55,917 shares of the specialty pharmaceutical company's stock valued at $1,131,000 after purchasing an additional 338 shares during the last quarter.
07/11/2017 - Flexion Therapeutics Inc had its "buy" rating reiterated by analysts at Janney Montgomery Scott. Public Employees Retirement System of OH now owns 41,644 shares of the specialty pharmaceutical company's stock worth $842,000 after buying an additional 17,066 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Flexion Therapeutics by 3.9% during the second quarter. The 20-day RSI for FLXN is 61.41%, which suggests that the stock is not particularly expensive or cheap, and not predisposed to a reactive price movement based on this measure. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company's stock valued at $2,047,000 after purchasing an additional 513 shares during the last quarter. Finally, Swiss National Bank raised its holdings in shares of Flexion Therapeutics by 13.2% during the first quarter. They may also be used to assist the trader figure out proper support and resistance levels for the stock.
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain.
Welsh fans were all tweeting about Aaron Ramsey after defeat to Ireland
I asked them to leave me alone as my contract has been running down and all the questions were getting asked. We're in campaigns and we're taking it to the wire, taking it to the last game and that's all we can do".